ABOS
Acumen Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.23
−3.80%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +22.8%
- EBIT
- +24.2%
- EPS
- +30.2%
- Free cash flow
- +28.9%
- Operating cash flow
- +28.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +20.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- -19.2%
- EBIT
- -8.6%
- Net income
- -18.6%
- EPS
- -17.0%
- Free cash flow
- -34.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026